Transarterial chemoembolization plus apatinib with or without camrelizumab for unresected hepatocellular carcinoma: A two-center propensity score matching study

PURPOSE: To compare the effectiveness and safety of transarterial chemoembolization (TACE) combined with apatinib and camrelizumab with those of TACE as well as apatinib among patients with unresectable hepatocellular carcinoma (HCC). MATERIALS AND METHODS: The data of patients with unresectable HCC...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Di, Ma, Kun, Yang, Wei, Zhou, Hai-Feng, Shi, Qi, Ren, Jian-Wu, Xie, Yu-Guan, Liu, Sheng, Shi, Hai-Bin, Zhou, Wei-Zhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9685301/
https://www.ncbi.nlm.nih.gov/pubmed/36439471
http://dx.doi.org/10.3389/fonc.2022.1057560

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9685301/
https://www.ncbi.nlm.nih.gov/pubmed/36439471
http://dx.doi.org/10.3389/fonc.2022.1057560

Ejemplares similares